News - Daiichi Sankyo

Filter

Current filters:

Daiichi Sankyo

Popular Filters

10 to 34 of 82 results

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo partners in new open innovation business funding

18-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and Mitsubishi UFJ Capital Co have agreed to launch a…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalResearch

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST

02-09-2013

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Positive Ph III results for Daiichi Sankyo's edoxaban in VTE

02-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has released encouraging results from the global Phase…

Cardio-vascularDaiichi SankyoedoxabanLixianaPharmaceuticalResearch

Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan

29-08-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has filed an application for approval in Japan to manufacture…

AmgenAsia-PacificDaiichi SankyoOncologyPharmaceuticalPraliaRanmarkRegulation

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Vifor Pharma's IV Ferinject reduces the need for further anemia treatment in kidney disease patients

10-07-2013

Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), has announced results which show…

Daiichi SankyoEuropeFerinjectInjectaferNephrology and HepatologyPharmaceuticalVifor Pharma

Germany's Saltigo to manufacture novel drug pipeline product for Daiichi Sankyo

08-07-2013

German custom manufacturing specialist Saltigo GmbH, a subsidiary of Lanxess (Xetra: LXS), has signed…

Daiichi SankyoLanxessPharmaceuticalProductionSaltigo GmbH

Japan vaccines briefs: Gardasil and Cervarix; Daiichi Sankyo files NDA

21-06-2013

The Japanese Ministry of Health, Labor and Welfare has decided to withdraw its recommendation for a vaccination…

Asia-PacificCervarixDaiichi SankyoGardasilGlaxoSmithKlineMerck & CoPharmaceuticalRegulationVaccinesWomen's Health

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

Ranbaxy highlights its actions on improved business and quality assurance

23-05-2013

Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of the biggest…

Daiichi SankyoGenericsManagementProductionRanbaxy LaboratoriesRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Daiichi Sankyo to support Phase I clinical study of anticoagulant activity reverser for edoxaban

25-04-2013

USA-based Perosphere and Japanese drug major Daiichi Sankyo(TYO: 4568) have entered into a clinical trial…

Cardio-vascularDaiichi SankyoedoxabanPER977PharmaceuticalResearch

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

US FDA sets new PDUFA action date for Vifor's Injectafer NDA

08-04-2013

Vifor Pharma, a unit of Switzerland's Galenica Group (SIX: GALN), says that its US partner, Luitpold…

Daiichi SankyoFerinjectGalenicaInjectaferLuitpold PharmaNorth AmericaPharmaceuticalRegulationVifor Pharma

Kowa and Daiichi Sankyo to end joint marketing partnership in Japan

07-04-2013

Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending…

Asia-PacificCardio-vascularDaiichi SankyoKowa PharmaceuticalsLicensingLivaloMarkets & MarketingOlmetecPharmaceutical

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry

25-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

10 to 34 of 82 results

Back to top